



## **PRESS RELEASE**

Stockholm, Sweden, March 23, 2005

### **ELEKTA NEUROMAG® RECEIVES REGULATORY APPROVAL IN CANADA**

**The worlds most advanced system for non-invasive registration of neuronal activity using magnetoencephalography (MEG) technology, is now available also for Canadian neurosurgery, neurology and psychiatry centers.**

On March 11, 2005, Health Canada – the Canadian federal health department – announced that Elekta Neuromag® is cleared for sale within the Canadian health care system.

MEG is a powerful tool for studying normal brain function as well as brain disorders, enhancing the ability to understand human brain function. Clinically, MEG is used to localize epileptic discharges in patients suffering from epilepsy and is also used to localize major functional centers in the brain that control motor, somatosensory, auditory, vision and language – information that is of high value in pre-surgical planning in neurosurgery.

With a 306 channel sensor array, Elekta Neuromag® is the world's most advanced MEG system, superior to alternatives by design. The system covers a larger brain area by using a more dense array of sensors. Elekta Neuromag® additionally deploys a unique dual sensor system – using both gradiometers and magnetometers – giving an unmatched representation of brain activity.

With the markets' lowest system noise and highest yield of information per temporal sample of the MEG field distribution, more useful information is acquired in each diagnostic session, further enhanced by the unique Signal Space Separation software from Elekta, which differentiates brain signals from external interference.

"The regulatory approval in Canada is an important step in our effort to broaden the market for this exciting new technology", says Anthony DeCarolis, President and CEO of Elekta, Inc. and head of Elekta's operations in North America. "We see a clear interest from leading institutions and are proud to invite Canadian researchers and clinicians to the growing international network of Elekta Neuromag® research centers.

\*\*\*\*\*

**For further information, please contact:**

#### **Product Enquiries**

Stephen Otto: Global MEG Sales and Marketing Coordinator  
Tel: +81 78 241 7100, e-mail: [stephen.otto@elekta.com](mailto:stephen.otto@elekta.com)



### **Investor Enquiries**

International: Peter Ejemyr, Group VP Corporate Communications  
Tel: +46 733 611 000, e-mail: [peter.ejemyr@elekta.com](mailto:peter.ejemyr@elekta.com)

United States: Lars Jonsteg, VP Investor Relations North America  
Tel: +46 708-783 735, e-mail: [lars.jonsteg@elekta.com](mailto:lars.jonsteg@elekta.com)

Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient.

For additional information about Elekta, please visit [www.elekta.com](http://www.elekta.com)